NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

MTA Autologous chondrocyte implantation for repairing symptomatic articular cartilage defects of the knee (including a review of TA89)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The interventions, ChondroCelect and MACI, require the use of animalderived products (namely from bovine or porcine origin). This may be an issue for people with particular religious and cultural beliefs who have objections to the use of certain animal products.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This issue will be brought to the Committee attention. However, NICE recommendations on interventions associated with animal-derived products do not pose an equality issue. When a topic is referred, the intervention is appraised for the population for which it is intended and the fact that some people may not be able accept the intervention cannot be addressed through any NICE recommendations.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

Technology appraisals: Scoping

Equality impact assessment for the proposed multiple technology appraisal of autologous chondrocyte implantation for repairing symptomatic articular cartilage defects of the knee (including a review of TA89) Issue date: May 2014

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): ...Elisabeth George......

Date: 16/05/2014